Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 5/20 | 0.48 |
| ▸ | FNTB | P49356 | 5/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215218 | 0.81 | PDK1 (0.52) | CA2CA1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1158033 | 0.79 | CA2 (0.69) | CA2CA1USP2ALDH1A1TP53 | |
| SCHEMBL9461939 | 0.79 | CA2 (0.69) | CA2CA1USP2ALDH1A1TP53 | |
| SCHEMBL1158031 | 0.79 | CA2 (0.69) | CA2CA1USP2ALDH1A1TP53 | |
| SCHEMBL775213 | 0.79 | GRN (0.59) | CA2CA1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11228098 | 0.78 | CA2 (0.68) | CA2CA1USP2ALDH1A1TP53 | |
| Water SCHEMBL28867161 | 0.78 | CA2 (0.67) | CA2CA1USP2ALDH1A1TP53 | |
| SCHEMBL6646636 | 0.78 | CA2 (0.67) | CA2CA1USP2ALDH1A1TP53 | |
| Lithium SCHEMBL6646645 | 0.78 | CA2 (0.67) | CA2CA1USP2ALDH1A1TP53 | |
| SCHEMBL3199823 | 0.78 | PDK1 (0.53) | CA2CA1SMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | CA2 901/4885CA1 216/4885SMN1; SMN2 206/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | CA2 901/4885CA1 216/4885SMN1; SMN2 206/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | CA2 768/4885CA1 153/4885SMN1; SMN2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.